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[57] ABSTRACT 
A novel class of compounds, knoWn as peptide nucleic 
acids, bind complementary ssDNA and RNA strands more 
strongly than a corresponding DNA. The peptide nucleic 
acids generally comprise ligands such as naturally occurring 
DNA bases attached to a peptide backbone through a suit 
able linker. 
11 Claims, N0 Drawings 
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PEPTIDE NUCLEIC ACIDS 
RELATED APPLICATION 
This application is a division of US. application Ser. No. 
08/054,363 ?led Apr. 26, 1993 (now US. Pat. No. 5,539, 
082), Which is a continuation-in-part of US. application Ser. 
No. 08/108,591 ?led Nov. 22, 1993, Which, in turn, is the 
US. national phase of PCT Application EP92/01219, ?led 
May 22, 1992 and published on Nov. 26, 1992, as WO 
92/20702 (noW abandoned). 
FIELD OF THE INVENTION 
This invention is directed to compounds that are not 
polynucleotides yet Which bind to complementary DNA and 
RNA strands. In particular, the invention concerns com 
pounds Wherein naturally-occurring nucleobases or other 
nucleobase-binding moieties are covalently bound to a 
polyamide backbone. 
BACKGROUND OF THE INVENTION 
Oligodeoxyribonucleotides as long as 100 base pairs (bp) 
are routinely synthesiZed by solid phase methods using 
commercially available, fully automatic synthesis machines. 
The chemical synthesis of oligoribonucleotides, hoWever, is 
far less routine. Oligoribonucleotides also are much less 
stable than oligodeoxyribonucleotides, a fact Which has 
contributed to the more prevalent use of oligodeoxyribo 
nucleotides in medical and biological research directed to, 
for example, gene therapy or the regulation of transcription 
or translation. 
The function of a gene starts by transcription of its 
information to a messenger RNA (mRNA) Which, by inter 
action With the ribosomal complex, directs the synthesis of 
a protein coded for by its sequence. The synthetic process is 
knoWn as translation. Translation requires the presence of 
various co-factors and building blocks, the amino acids, and 
their transfer RNAs (tRNA), all of Which are present in 
normal cells. 
Transcription initiation requires speci?c recognition of a 
promoter DNA sequence by the RNA-synthesizing enZyme, 
RNA polymerase. In many cases in prokaryotic cells, and 
probably in all cases in eukaryotic cells, this recognition is 
preceded by sequence-speci?c binding of a protein tran 
scription factor to the promoter. Other proteins Which bind 
to the promoter, but Whose binding prohibits action of RNA 
polymerase, are knoWn as repressors. Thus, gene activation 
typically is regulated positively by transcription factors and 
negatively by repressors. 
Most conventional drugs function by interaction With and 
modulation of one or more targeted endogenous proteins, 
e.g., enZymes. Such drugs, hoWever, typically are not spe 
ci?c for targeted proteins but interact With other proteins as 
Well. Thus, a relatively large dose of drug must be used to 
effectively modulate a targeted protein. Typical daily doses 
of drugs are from 10_5—5_1 millimoles per kilogram of body 
Weight or 10_3—10 millimoles for a 100 kilogram person. If 
this modulation instead could be effected by interaction With 
and inactivation of mRNA, a dramatic reduction in the 
necessary amount of drug necessary could likely be 
achieved, along With a corresponding reduction in side 
effects. Further reductions could be effected if such interac 
tion could be rendered site- speci?c. Given that a function 
ing gene continually produces mRNA, it Would thus be even 
more advantageous if gene transcription could be arrested in 
its entirety. 
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Oligodeoxynucleotides offer such opportunities. For 
example, synthetic oligodeoxynucleotides could be used as 
antisense probes to block and eventually lead to the break 
doWn of mRNA. Thus, synthetic DNA could suppress 
translation in vivo. It also may be possible to modulate the 
genome of an animal by, for example, triple helix formation 
using oligonucleotides or other DNA recogniZing agents. 
HoWever, there are a number of draWbacks associated With 
triple helix formation. For example, it can only be used for 
homopurine sequences and it requires unphysiologically 
high ionic strength and loW pH. 
Furthermore, unmodi?ed oligonucleotides are unpractical 
both in the antisense approach and in the triple helix 
approach because they have short in vivo half-lives, they are 
dif?cult to prepare in more than milligram quantities and, 
thus, are prohibitively costly, and they are poor cell mem 
brane penetrators. 
These problems have resulted in an extensive search for 
improvements and alternatives. For example, the problems 
arising in connection With double-stranded DNA (dsDNA) 
recognition through triple helix formation have been dimin 
ished by a clever “sWitch back” chemical linking Whereby a 
sequence of polypurine on one strand is recogniZed, and by 
“sWitching back”, a homopurine sequence on the other 
strand can be recogniZed. See, e.g., McCurdy, Moulds, and 
Froehler, Nucleosides Nucleotides 1991 10, 287. Also, good 
helix formation has been obtained by using arti?cial bases, 
thereby improving binding conditions With regard to ionic 
strength and pH. 
In order to improve half life as Well as membrane 
penetration, a large number of variations in polynucleotide 
backbones has been undertaken, although so far not With the 
desired results. These variations include the use of 
methylphosphonates, monothiophosphates, 
dithiophosphates, phosphoramidates, phosphate esters, 
bridged phosphoroamidates, bridged phosphorothioates, 
bridged methylenephosphonates, dephospho internucleotide 
analogs With siloxane bridges, carbonate bridges, carboxym 
ethyl ester bridges, acetamide bridges, carbamate bridges, 
thioether, sulfoxy, sulfono bridges, various “plastic” DNAs, 
ot-anomeric bridges, and borane derivatives. 
The great majority of these backbone modi?cations led to 
decreased stability for hybrids formed betWeen the modi?ed 
oligonucleotide and its complementary native 
oligonucleotide, as assayed by measuring Tm values. 
Consequently, it is generally understood in the art that 
backbone modi?cations destabiliZe such hybrids, i.e., result 
in loWer Tm values, and should be kept to a minimum. 
OBJECTS OF THE INVENTION 
It is one object of the present invention to provide 
compounds that bind ssDNA and RNA strands to form stable 
hybrids thereWith. 
It is a further object of the invention to provide com 
pounds that bind ssDNA and RNA strands. 
It is another object to provide compounds Wherein 
naturally-occurring nucleobases or other nucleobase 
binding moieties are covalently bound to a peptide back 
bone. 
It is yet another object to provide compounds other than 
RNA that can bind one strand of a double-stranded 
polynucleotide, thereby displacing the other strand. 
It is still another object to provide therapeutic, diagnostic, 
and prophylactic methods that employ such compounds. 
SUMMARY OF THE INVENTION 
The present invention provides a novel class of 
compounds, knoWn as peptide nucleic acids (PNAs), that 
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bind complementary ssDNA and RNA strands. The com 
pounds of the invention generally comprise ligands linked to 
a peptide backbone. Representative ligands include either 
the four main naturally occurring DNA bases (i.e., thymine, 
cytosine, adenine or guanine) or other naturally occurring 
nucleobases (e.g., inosine, uracil, 5-methylcytosine or 
thiouracil) or arti?cial bases (e.g., bromothymine, aZaad 
enines or aZaguanines, etc.) attached to a peptide backbone 
through a suitable linker. 
In WO 92/20702, We described PNAs Wherein such 
ligands are linked to a polyamide backbone solely through 
aZa nitrogen atoms. The PNAs of the invention differ from 
those disclosed in WO 92/20702 principally in that their 
recognition moieties are linked to the polyamide backbone 
additionally through amido and/or ureido tethers. 
In certain preferred embodiments, the peptide nucleic 
acids of the invention have the general formula (I): 
I1 l2 L” (I) | 
A1 A2 An 
I | | 
2 J" Z 
n is at least 2, 
each of L1—L” is independently selected from the group 
consisting of hydrogen, hydroXy, (C1—C4)alkanoyl, 
naturally occurring nucleobases, non-naturally occur 
ring nucleobases, aromatic moieties, DNA 
intercalators, nucleobase-binding groups, heterocyclic 
moieties, and reporter ligands, at least one of L1—L” 
being a naturally occurring nucleobase, a non-naturally 
occurring nucleobase, a DNA intercalator, or a 
nucleobase-binding group; 
each of T1—T” is (CR6R7)y Where R6 is hydrogen and R7 
is selected from the group consisting of the side chains 
of naturally occurring alpha amino acids, or R6 and R7 
are independently selected from the group consisting of 
hydrogen, (C2—C6)alkyl, aryl, aralkyl, heteroaryl, 
hydroXy, (C1—C6) alkoXy, (C1—C6) alkylthio, NR3R4 
and SR5, Where R3 and R4 are as de?ned beloW, and R5 
is hydrogen, (C1—C6) alkyl, hydroXy-, alkoXy-, or 
alkylthio- substituted (C1—C6) alkyl, or R6 and R7 taken 
together complete an alicyclic or heterocyclic system; 
each of D1—D” is (CRGR7 Z Where R6 and R7 are as de?ned 
above; 
each of y and Z is Zero or an integer from 1 to 10, the sum 
y+Z being greater than 2 but not more than 10; 
each of G1—G"_1 is —NR3CO—, —NR3CS—, 
—NR3SO— or —NR3SO2—, in either orientation, 
Where R3 is as de?ned above; 
each pair of A1—A” and J1—J” are selected such that: 
(a) A is a group of formula (11a), (11b) or (11c) and J is 
Rh 
15 
3O 
35 
40 
(b) A is a group of formula (11d) and J is CH; 
R2 R2 R2 R2 
i .4 r i .4 S r S 
XR3 
Where: 
X is O, S, Se, NR3, CH2 or C(CH3)2; 
Y is a single bond, O, S or NR4; 
each of r and s is Zero or an integer from 1 to 5, the sum 
r+s being not more than 10; 
each R1 and R2 is independently selected from the group 
consisting of hydrogen, (C1—C4) alkyl Which may be 
hydroXy- or alkoXy- or alkylthio-substituted, hydroXy, 
alkoXy, alkylthio, amino and halogen; 
—NR3SO— or —NR3SO2—, in either orientation, 
Where R3 is as de?ned above; 
an activated derivative of —CO2H or —SO3H; and 
Z is —NHR1OR11 or —NR1OC(O)R11, Where R8, R9, R10 
and R11 are independently selected from the group 
consisting of hydrogen, alkyl, amino protecting groups, 
reporter ligands, intercalators, chelators, peptides, 
proteins, carbohydrates, lipids, steroids, oligonucle 
otides and soluble and non-soluble polymers. 
In certain embodiments, at least one A is a group of 
formula (11c) and J is N or R3N+. In other embodiments, A 
is a group of formula (IIa) or (IIb), J is N or R3N+, and at 
least one of y or Z is not 1 or 2. 
Preferred peptide nucleic acids have general formula 
(IIIa) or (IIIb): 
(IIIa) 
5,773,571 
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-continued 
L L (IIIb) \(?H?l \KiHDI 
O NR3 0 NR3 
Y O T 
CH m 
Rh (CH2) NV (CH2)m\ (CHQN \/< 2) \NH—Ri 
H , 
, R7 
0 R7 1, n P 
10 
wherein: 
L 
each L is independently selected from the group consist- | (vma) 
ing of hydrogen, phenyl, heterocyclic moieties, natu- 0 (CH2)! 
rally occurring nucleobases, and non-naturally occur- 15 
ring nucleobases; Ho\n/ (CH2) NV (CHZ)"‘\NHZ 
each R7’ is independently selected from the group con- 0 R7‘ 
sisting of hydrogen and the side chains of naturally L ( b) 
. . . _ VIII 
‘occurring alpha amino acids, 20 \(CHZ)I 
n is an integer from 1 to 60; N/g 
each of k, l, and m is independently Zero or an integer R3 0 
from 1 to 5; HO (CH2) (CH2)m \ 
p is Zero or 1; \(l; R7, NHZ 
Rh is OH, NH2 or —NHLysNH2; and 25 p 
R is H or COCH3. L (VIIIc) 
Particularly preferred are compounds having formula \“iHZW 
(IIIa) or (IIIb) Wherein each L is independently selected 0 NR3 
from the group consisting of the nucleobases thymine (T), 30 Y 
adenine (A), cytosine (C), guanine (G) and uracil (U), k and HO (CH2) NV (CHZ)m\ 
m are Zero or 1, and n is an integer from 1 to 30, in particular \n/ NHZ 
from 4 to 20. 0 R7‘ 
The peptide nucleic acids of the invention are synthesiZed _ p _ _ _ _ 
by adaptation of standard peptide synthesis procedures, 35 QT am1n0'Pr0teCted_and_/0r acld termlnal actlvated dffnwb 
either in solution or on a solid phase. The synthons used are ?ves thereon Wherem L 15 select?d from the group Conslsnng 
Specially monomer amino acids or their activated of hydrogen, phenyl, heterocycl1c mo1et1es,~naturally occur 
derivatives, protected by standard protecting groups. The nng H171? leobases’ and non-naturally OCCufrlng nucleobases; 
oligonucleotide analogs also can be synthesiZed by using the and R 1.5 selecled from the group “.mslsnng of hydrogen 
d. d. .d d d. . 40 and the side chains of naturally occurring alpha amino acids. 
corrfiigonthlélgnolvaél tig?omgmgllgtst'lons according to the Unexpectedly, these compounds also are able to recogniZe 
_ _ ’ _ _ _ dupleX DNA by displacing one strand, thereby presumably 
m‘fgnngn age selgcééd from ttlhe group conlslfstmg ff ‘ammo generating a double heliX With the other one. Such recog 
acl S> M61 5 an lammes avlng genera Ormu ae- n1t1on can take place to dsDNA sequences 5—60 base pairs 
long. Sequences betWeen 10 and 20 bases are of interest 
II“ II“ 45 since this is the range Within Which unique DNA sequences 
A A of prokaryotes and eukaryotes are found. Reagents Which 
I I recognize 17—18 bases are of particular interest since this is 
J Or J Or the length of unique sequences in the human genome. The \ / \ / \ / \ / 
T D T T compounds of the invention are able to form triple helices 
(IV) (V) 50 With dsDNA and double helices With RNA or ssDNA. The 
compounds of the invention also are able to form triple 
Tr helices Wherein a ?rst PNA strand binds With RNA or 
A ssDNA and a second PNA strand binds With the resulting 
| double heliX or With the ?rst PNA strand. 
M\ /J\ /M 55 Whereas the improved binding of the compounds of the 
T D invention should render them efficient as antisense agents, it 
(VI) is eXpected that an eXtended range of related reagents may 
cause strand displacement, noW that this surprising and 
_ unexpected neW behavior of dsDNA has been discovered. 
Where1n_L, A L T and D We as de?ned above> except that 60 Thus, in one aspect, the present invention provides meth 
any ammo groups Fherem may be Protected by ammo ods for inhibiting the eXpression of particular genes in the 
PrQteCnng gr911PS_;E 1S COOH> CSOH>_SOOH>3SO2OH3Or1a2n cells of an organism, comprising administering to said 
331223;; giseivgélggeghzggig ailtzidRbl/lz agile-112m? N? > organism a reagent as de?ned above Which binds speci? 
Pro 66 mg cally to sequences of said genes. 
group- 65 Further, the invention provides methods for inhibiting 
Preferred monomer synthons according to the invention 
have formula (VIIIa)—(VIIIc): 
transcription and/or replication of particular genes or for 
inducing degradation of particular regions of double 
5,773,571 
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stranded DNA in cells of an organism by administering to 
said organism a reagent as de?ned above. 
Still further, the invention provides methods for killing 
cells or virus by contacting said cells or virus With a reagent 
as de?ned above Which binds speci?cally to sequences of 
the genome of said cells or virus. 
DETAILED DESCRIPTION OF THE 
INVENTION 
In the oligonucleotide analogs and monomer synthons 
according to the invention, ligand L is primarily a naturally 
occurring nucleobase attached at the position found in 
nature, i.e., position 9 for adenine or guanine, and position 
1 for thymine or cytosine. Alternatively, L may be a non 
naturally occurring nucleobase (nucleobase analog), another 
base-binding moiety, an aromatic moiety, (C1—C4)alkanoyl, 
hydroxy or even hydrogen. It Will be understood that the 
term nucleobase includes nucleobases bearing removable 
protecting groups. Some typical nucleobase ligands and 
illustrative synthetic ligands are shoWn in FIG. 2 of WO 
92/20702. Furthermore, L can be a DNA intercalator, a 
reporter ligand such as, for example, a ?uorophor, radio 
label, spin label, hapten, or a protein-recognizing ligand 
such as biotin. In monomer synthons, L may be blocked With 
protecting groups, as illustrated in FIG. 4 of WO 92/20702. 
Linker A can be a Wide variety of groups such as 
—CR1R2CO—, —CR1R2CS—, —CR1R2CSe—, 
—CR1R2CNHR3—, —CR1R2C=CH2— and —CR1R2C=C 
(CH3)2—, Where R1, R2 and R3 are as de?ned above. 
Preferably, A is methylenecarbonyl (—CH2CO—), amido 
(—CONR3—), or ureido (—NR3CONR3—) . Also, Acan be 
a longer chain moiety such as propanoyl, butanoyl or 
pentanoyl, or corresponding derivative, Wherein O is 
replaced by another value of X or the chain is substituted 
With RlR2 or is heterogenous, containing Y. Further, A can 
be a (C2—C6)alkylene chain, a (C2—C6) alkylene chain sub 
stituted With RlR2 or can be heterogenous, containing Y. In 
certain cases, A can just be a single bond. 
In one preferred form of the invention, B is a nitrogen 
atom, thereby presenting the possibility of an achiral back 
bone. B can also be R3N+, Where R3 is as de?ned above, or 
CH. 
In the preferred form of the invention, C is —CR6R7—, 
but can also be a tWo carbon unit, i.e. —CHR6CHR7— or 
—CR6R7CH2—, Where R6 and R7 are as de?ned above. R6 
and R7 also can be a heteroaryl group such as, for example, 
pyrrolyl, furyl, thienyl, imidaZolyl, pyridyl, pyrimidinyl, 
indolyl, or can be taken together to complete an alicyclic 
system such as, for example, 1,2-cyclobutanediyl, 1,2 
cyclopentanediyl or 1,2-cyclohexanediyl. 
In the preferred form of the invention, E in the monomer 
synthon is COOH or an activated derivative thereof, and G 
in the oligomer is —CONR3—. As de?ned above, E may 
also be CSOH, SOOH, SOZOH or an activated derivative 
thereof, Whereby G in the oligomer becomes —CSNR3—, 
—SONR3— and —SO2NR3—, respectively. The activation 
may, for example, be achieved using an acid anhydride or an 
active ester derivative, Wherein hydrogen in the groups 
represented by E is replaced by a leaving group suited for 
generating the groWing backbone. 
The amino acids Which form the backbone may be 
identical or different. We have found that those based on 
2-aminoethylglycine are especially Well suited to the pur 
pose of the invention. 
In some cases it may be of interest to attach ligands at 
either terminus (Q, I) to modulate the binding characteristics 
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of the PNAs. Representative ligands include DNA interca 
lators Which Will improve dsDNA binding or basic groups, 
such as lysine or polylysine, Which Will strengthen the 
binding of PNA due to electrostatic interaction. To decrease 
negatively charged groups such as carboxy and sulfo groups 
could be used. The design of the synthons further alloWs 
such other moieties to be located on non-terminal positions. 
In a further aspect of the invention, the PNAoligomers are 
conjugated to loW molecular effector ligands such as ligands 
having nuclease activity or alkylating activity or reporter 
ligands (?uorescent, spin labels, radioactive, protein recog 
nition ligands, for example, biotin or haptens). In a further 
aspect of the invention, the PNAs are conjugated to peptides 
or proteins, Where the peptides have signaling activity and 
the proteins are, for example, enZymes, transcription factors 
or antibodies. Also, the PNAs can be attached to Water 
soluble or Water-insoluble polymers. In another aspect of the 
invention, the PNAs are conjugated to oligonucleotides or 
carbohydrates. When Warranted, a PNA oligomer can be 
synthesiZed onto some moiety (e.g., a peptide chain, 
reporter, intercalator or other type of ligand-containing 
group) attached to a solid support. 
Such conjugates can be used for gene modulation (e.g., 
gene targeted drugs), for diagnostics, for biotechnology, and 
for scienti?c purposes. 
As a further aspect of the invention, PNAs can be used to 
target RNA and ssDNA to produce both antisense-type gene 
regulating moieties and hybridiZation probes for the identi 
?cation and puri?cation of nucleic acids. Furthermore, the 
PNAs can be modi?ed in such a Way that they can form 
triple helices With dsDNA. Reagents that bind sequence 
speci?cally to dsDNA have applications as gene targeted 
drugs. These are foreseen as extremely useful drugs for 
treating diseases like cancer, AIDS and other virus 
infections, and may also prove effective for treatment of 
some genetic diseases. Furthermore, these reagents may be 
used for research and in diagnostics for detection and 
isolation of speci?c nucleic acids. 
The triple helix principle is believed to be the only knoWn 
principle in the art for sequence-speci?c recognition of 
dsDNA. HoWever, triple helix formation is largely limited to 
recognition of homopurine-homopyrimidine sequences. 
Strand displacement is superior to triple helix recognition in 
that it alloWs for recognition of any sequence by use of the 
four natural bases. Also, in strand displacement recognition 
readily occurs at physiological conditions, that is, neutral 
pH, ambient (20°—40° C.) temperature and medium 
(100—150 mM) ionic strength. 
Gene targeted drugs are designed With a nucleobase 
sequence (containing 10—20 units) complementary to the 
regulatory region (the promoter) of the target gene. 
Therefore, upon administration of the drug, it binds to the 
promoter and block access thereto by RNA polymerase. 
Consequently, no mRNA, and thus no gene product 
(protein), is produced. If the target is Within a vital gene for 
a virus, no viable virus particles Will be produced. 
Alternatively, the target could be doWnstream from the 
promoter, causing the RNA polymerase to terminate at this 
position, thus forming a truncated mRNA/protein Which is 
nonfunctional. 
Sequence-speci?c recognition of ssDNA by base comple 
mentary hybridiZation can likeWise be exploited to target 
speci?c genes and viruses. In this case, the target sequence 
is contained in the mRNA such that binding of the drug to 
the target hinders the action of ribosomes and, consequently, 
translation of the mRNA into protein. The peptide nucleic 
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acids of the invention are superior to prior reagents in that 
they have signi?cantly higher affinity for complementary 
ssDNA. Also, they possess no charge and are Water soluble, 
Which should facilitate cellular uptake, and they contain 
amides of non-biological amino acids, Which should make 
them biostable and resistant to enZymatic degradation by, for 
example, proteases. 
It is believed that PNA oligomers according to the inven 
tion exhibit biochemical/biological properties similar to 
those disclosed in WO 92/20702, and that such properties 
can be determined by similar means. It also is believed that 
the PNAs of the invention can be synthesiZed by similar 
methodology. Monomer synthons according to the invention 
are coupled using the standard protocols to give the desired 
oligomeric sequences. 
One monomer synthon according to the invention is 
prepared by reacting glycinamide hydrochloride 1 With ethyl 
acrylate in the presence of an acid scavenging base to give 
the Michael adduct, N-carboxamidomethyl-[3-alanine ethyl 
ester 2. The adduct 2 is condensed With 1-carboxymethyl 
thymine 3 using diisopropylcarbodiimide and hydroxyben 
ZotriaZole to give (N-carboxamidomethyl)-N-(1-(thymin-1 
yl)acetyl)-[3-alanine ethyl ester 4. The primary amide of 4 is 
oxidiZed and rearranged to the Boc-protected amine With 
sodium hypobromite in t-butanol to provide (N-t 
butyloxycarbonylaminomethyl)-N-(1-(thymin-1-yl)acetyl) 
[3-alanine ethyl ester 5. The ethyl ester is hydrolyZed With 
aqueous base to provide the thymine-based monomer, (N-t 
butyloxycarbonylaminomethyl)-N-(1-(thymin-1-yl)acetyl) 
[3-alanine 6. This reaction sequence is folloWed to prepare 
the corresponding C, G, and A -based monomers, namely, 
N-(t-butyloxycarbonylaminomethyl)-N-(1 -(N4 
benZyloxycarbonyl-cytosin-1-yl)acetyl)-[3-alanine, N-(t 
butyloxycarbonyl- aminomethyl-N-(1-(2-amino-6 
benZyloxy-purin-9-yl) acetyl) - [3 -alanine, N-(t 
butyloxycarbonylaminomethyl)-N-(1-(N° 
benZyloxycarbonyl-adenine-9-yl)acetyl)-[3-alanine. 
A further monomer synthon is prepared by reacting 
1-aminothymine With triphosgene to give the carbamoyl 
chloride derivative, 8, Which is condensed With N-(2-t 
butyloxycarbonylaminoethyl)glycine ethyl ester and an acid 
scavenger to yield the fully protected monomer, 9. The ester 
is hydrolyZed to give the useful monomer, 10. This reaction 
sequence is folloWed to prepare the corresponding C, G, and 
A -based monomers, namely, N-(t 
butyloxycarbonylaminoethyl)-N-(1-N4-benZyloxycarbonyl 
cytosin-1 -yl)aminocarbonyl)-glycine, N-(t 
butyloxycarbonylaminoethyl)-N-(1-(2-amino-6-benZyloxy 
purin-9-yl)-aminocarbonyl)-glycine, N-(t 
butyloxycarbonyl-amino ethyl)-N-(1-(N° 
benZyloxycarbonyl-adenine-9-yl)aminocarbonyl)-glycine. 
A further monomer synthon is prepared by converting 
2-hydroxy-5- (t-butyloxycarbonylamino) pentanoic acid 
ethyl ester to its aZido analog via the use of diphenyl 
phosphoryl aZide, DEAD, and triphenylphosphine generally 
by the procedure described in Tetrahedron Letters, (1977), p. 
1977. The aZido compound, 12, Was converted to the 
iminophosphorane, 13, and used immediately in a high 
pressure reaction With carbon dioxide to convert it into 
isocyanate, 14. The isocyanate is condensed With thymine to 
give the fully protected monomer, 15, Which is hydrolyZed 
to the actual monomer, 16, using hydroxide. This reaction 
sequence is folloWed to prepare the corresponding C, G, and 
A -based monomers, namely, 5 -(t-butyloxycarbonylamino) 
-2-((N4-benZyloxycarbonyl-cytosin-1-yl)carbonylamino 
pentanoic acid ethyl ester, 5 -(t-butyloxycarbonylamino-2-( 
(2-amino-6-benZyloxy-purin-9-yl)carbonylamino) 
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pentanoic acid ethyl ester, 5-(t-butyloxycarbonylamino)-2-( (N6-benZyloxycarbonyl-adenine-9-yl)carbonylamino) 
pentanoic acid ethyl ester. 
Additional objects, advantages, and novel features of this 
invention Will become apparent to those skilled in the art 
upon examination of the folloWing examples thereof, Which 
are not intended to be limiting. 
EXAMPLE 1 
N-carboxamidomethyl-[3-alanine ethyl ester, 2. 
Glycinamide hydrochloride (1, 11.0 g, 0.10 mol) is sus 
pended in 500 mL of dioxane and diisopropylethylamine 
(12.9 g, 0.10 mol) is added and the mixture cooled to 00 C. 
With stirring ethyl acrylate (10.0 g, 0.10 mol) is added 
dropWise over 15 minutes. After the addition is complete the 
reaction is alloWed to Warm to room temperature and stir for 
12 hours. The reaction mixture is diluted With Water 1.5 L 
and the pH adjusted to 4. The solution is extracted With 
diethyl ether (3x300 mL) . The aqueous layer is neutraliZed 
With sodium hydroxide and extracted 5 times With dichlo 
romethane. The dichloromethane extracts are combined, 
dried (Na2SO4), and the solvent removed to give a solid. 
EXAMPLE 2 
(N-carboxamidomethyl)-N-(1-(thymin-1-yl)acetyl) 
[3-alanine ethyl ester, 4. 
The product from Example 1, 2, is dissolved in dichlo 
romethane (500 mL) and to this is added 1-carboxymethyl 
thymine (3, 15.5 g, 0.1 mol), hydroxybenZotriaZole (13.5 g, 
0.1 mol) and the solution is cooled to 00 C. in an ice bath. 
Diisopropylcarbodiimide (12.6 g, 0.1 mol) dissolved in So 
mL of dichloromethane is added in one portion and the 
reaction is stirred for 12 hours. The suspended solids are 
removed by ?ltration and Washed With dichloromethane. 
The solution is evaporated to a solid and the desired product, 
4, is obtained after chromatography on silica gel using 
dichloromethane/ethanol as eluent. 
EXAMPLE 3 
(N-t-butyloxycarbonylaminomethyl)-N-(1-(thymin 
1-yl)acetyl)-[3-alanine ethyl ester, 5. 
The product from Example 2, 4, is dissolved t-butanol/ 
dioxane (4:1, 500 mL), cooled to 00 C., and sodium hypo 
bromite solution (0.15 mol) is added. After 6 hours the 
reaction mixture is evaporated to remove volatile solvents 
and the residue is diluted With Water (500 mL) and extracted 
(5x200 mL) With dichloromethane. The extracts are 
combined, dried, and evaporated to a solid. 
EXAMPLE 4 
(N-t-butyloxycarbonylaminomethyl)-N-(1-(thymin 
1-yl)acetyl)-[3-alanine, 6. 
The product from Example 3, 5, is dissolved in ethanol 
(500 mL) and 5M sodium hydroxide (20 mL) is added. The 
solution is stirred for 6 hours, then neutraliZed With 5N 
hydrochloric acid (20 mL) and the solution evaporated to a 
solid. This solid is recrystalliZed to give the title compound. 
EXAMPLE 5 
1-(Chlorocarbonylamino)-thymine, 8. 
1-Amino thymine (7, 12.5 g, 0.1 mol) is dissolved in 
tetrahydrofuran (500 mL) and the solution is cooled to 0° C. 
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and a 2M solution of triphosgene in THE (150 mL) is added 
and the reaction is stirred for 4 hours. The solution is 
evaporated to a solid, Which is used as is in the next reaction. 
EXAMPLE 6 
N-(2-t-Butyloxycarbonylaminoethyl)-N-(thymin-1 
yl-amino-carbonyl)glycine ethyl ester, 9. 
The product from Example 5, 8, is dissolved in THE (500 
mL) and diisopropylethylamine (12.9 g, 0.1 mol) is added, 
folloWed by N-(2-t-butyloxycarbonylaminoethyl)glycine 
ethyl ester (24.6 g, 0.1 mol) and the solution stirred for 12 
hours. The reaction is diluted With 1000 mL of diethyl ether 
and extracted 3 times With 0.1N HC1 solution. The organic 
layer is Washed With diluted sodium bicarbonate solution, 
dried, ?ltered and evaporated to give a solid. 
EXAMPLE 7 
N-(2-t-Butyloxycarbonylaminoethyl) -N-(thymin- 1 
yl-amino-carbonyl)glycine, 10. 
The product from Example 6, 9, is dissolved in ethanol 
(500 mL) and 2M sodium hydroxide (50 mL) is added. The 
reaction is stirred for 6 hours, then neutraliZed With 50 mL 
of 2M HC1 solution, and evaporated to remove the ethanol. 
The residue is dissolved in dichloromethane (250 mL) and 
is extracted With Water (2x50 mL), dried, ?ltered, and 
evaporated to a solid. 
EXAMPLE 8 
2-AZido-5-(t-butyloxycarbonylamino)pentanoic acid 
ethyl ester, 12. 
2-Hydroxy-5-(t-butyloxycarbonylamino)pentanoic acid 
ethyl ester, (11, 26.1 g, 0.1 mol), triphenylphosphine (26.2 g, 
0.10 mol), diethylaZodicarboxylate (17.4 g, 0.1 mol), and 
diphenylphosphorylaZide (27.5 g, 0.1 mol) is dissolved in 
THE (500 mL) and heated to re?ux and maintained there for 
8 hours. The reaction is cooled to room temperature, evapo 
rated to an oil, and the product isolated by column chroma 
tography using dichloromethanezethanol as eluent. 
EXAMPLE 9 
2-Iminotriphenylphosphoranyl-5-(t 
butyloxycarbonylamino)pentanoic acid ethyl ester, 
13. 
The product, 12, from Example 8 is dissolved in THF and 
triphenylphosphine (26.2 g, 0.1 mol) is added and the 
reaction is stirred for 4 hours. This solution is used as is for 
the next reaction (Example 10). 
EXAMPLE 10 
2-Isocyanato-5-(t-butyloxycarbonylamino)pentanoic 
acid ethyl ester, 14. 
The reaction solution from Example 9 is placed in a Parr® 
bomb and carbon dioxide (22 g, 0.5 mol) is condensed into 
the bomb. The bomb is sealed and heated to 50° C. for 12 
hours. The bomb is cooled and vented to atmospheric 
pressure. The solution is transferred from the bomb to a ?ask 
and used as is in the next reaction (Example 11). 
EXAMPLE 11 
2-(Thymin-1-ylcarbonylamino)-5-(t 
butyloxycarbonylamino)pentanoic acid ethyl ester, 
15. 
The reaction solution from Example 10 is placed in a ?ask 
and to this is added thymine (12.6 g, 0.1 mol) . The resulting 
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solution is alloWed to stir for 12 hours, then is evaporated to 
a solid, Which is puri?ed by column chromatography using 
dichlormethanezethanol as the eluent. 
EXAMPLE 12 
2-(Thymin-1 -ylcarbonylamino)-5 -(t 
butyloxycarbonyl- amino)pentanoic acid, 1 6. 
The product from Example 11, 15, is dissolved in ethanol 
(500 mL) and to this added 2M sodium hydroxide (50 mL) 
and the reaction stirred for 12 hours. The reaction is neu 
traliZed With 2M HC1 solution (50 mL) and evaporated to a 
small volume. This residue is diluted With Water (250 mL) 
and extracted With dichloromethane (4><100 mL), dried, 
?ltered, and evaporated to give a solid. 
EXAMPLE 13 
1 -(2(-Thyminyl)acetyl)- 1-(2-(tBoc-aminopropyl)) 
glycine, 17 
1,3-Diaminopropane (0.05 mmol) Was dissolved in THE 
(100 mL) and chloroacetic acid (0.045 mmol) Was added and 
the reaction heated at re?ux for 4 hours and cooled to room 
temperature. The solution Was diluted With diethyl ether 
(500 mL) and extracted 3 times With 1N NaOH solution. The 
combined Water layers Were acidi?ed to pH=4 and extracted 
With dichloromethane (5x50 mL). The organic layers Were 
combined, dried, ?ltered and evaporated to an oil. This oil 
Was dissolved in methanol (1000 mL) and dry HCl gas 
added. The reaction Was heated to re?ux and maintained 
there for 8 hours. The reaction Was cooled and evaporated to 
an oil. This oil Was dissolved in dioxane/Water and 
p-nitrophenyl-t-butylcarbonate (0.05 mmol) Was added and 
the pH adjusted to 10. The reaction Was stirred for 4 hours, 
then neutraliZed and extracted 5 times With dichlo 
romethane. The methyl ester Was dissolved in 50% DMF in 
dichloromethane and to this Was added dicyclohexylcarbo 
diimide (DCC, 0.05 mmol) and hydroxbenZotriaZole (0.05 
mmol), and 2-thyminylacetic acid (0.05 mmol). The reaction 
Was stirred for 18 hours then the DCC Was removed by 
?ltration and the residue evaporated to an oil. The oil Was 
puri?ed by column chromatography. 
EXAMPLE 14 
3-(Boc-amino)-1,2-propanediol, 18 
3-Amino-1,2-propanediol (40.00 g, 0.440 mol, 1.0 eqv) 
Was dissolved in Water (1000 ml) and cooled to 0° C., and 
di-tert-butyl dicarbonate (115.0 g, 0.526 mol, 1.2 eqv) Was 
added in one portion. The reaction mixture Was heated to 
room temperature on a Water bath With stirring. The pH Was 
maintained at 10.5 With a solution of sodium hydroxide 
(17.56 g, 0.440 mol, 1.0 eqv) in Water (120 ml). When the 
addition of aqueous sodium hydroxide Was completed, the 
reaction mixture Was stirred overnight at room temperature. 
Subsequently, ethyl acetate (750 ml) Was added to the 
reaction mixture folloWed by cooling to 0° C. and the pH 
Was adjusted to 2.5 With 4N sulfuric acid With vigorous 
stirring. The phases Were separated. The Water phase Was 
Washed With additional ethyl acetate (6x350 ml). The vol 
ume of the organic phase Was reduced to 900 ml by 
evaporation under reduced pressure and Washed With a 
saturated aqueous solution of potassium hydrogen sulfate 
diluted to tWice its volume (1><1000 ml) and With saturated 
aqueous sodium chloride (1><500 ml). The organic phase Was 
dried (MgSO4) and evaporated under reduced pressure to 
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yield 50.12 9 (60%) of the title compound. The product 
could be solidi?ed by evaporation from methylene chloride 
and subsequent freezing. 1H-NMR (CDCl3/T MS): 6=1.43 
(s, 9H, Me3C), 3.25 (m, 2H, CH2), 3.57 (m, 2H, CH2), 3.73 
(m, 1H, CH). 13C-NMR (CDCl3/TMS): 6=28.2 (Me3C), 
42.6 (CH2), 63.5, 71.1 (CHZOH, CHOH), 79.5 (Me3C), 
157.0 (C=O). 
EXAMPLE 15 
Boc-aminoacetaldehyde, 19 
3-(Boc-amino)-1,2-propanediol (18, 20.76 g, 0.109 mol, 1 
eqv) Was suspended in Water (150 ml). Potassium 
m-periodate (24.97 g, 0.109 mol, 1 eqv) Was added and the 
reaction mixture Was stirred for 2 h at room temperature 
under nitrogen. The reaction mixture Was ?ltered and the 
Water phase Was extracted With chloroform (6x250 ml). The 
organic phase Was dried (MgSO4) and evaporated to afford 
crude Boc-aminoacetaldehyde as a golden oil. This oil Was 
kugelrohr distilled at 80° C. and 0.2 mbar to yield 13.19 g 
(76%) of the title compound as a semicrystalline solid. 
1HNMR (DMSO-dG/TMS): 6=1.47 (s, 9H, Me3C), 3.81 (d, 
J=5.6 HZ, 2H, CH2), 7.22 (b, 1H, NH), 9.54 (s, 1H, CHO). 
13C-NMR (DMSO-dG/TMS): 6=28.2 (Me3C), 50.5 (CH2), 
78.4 (Me3C), 156.1 (carbamate C=O), 200.6 (CHO). Anal. 
Calcd. for C7H13NO3: C, 52.82; H, 8.23; N, 8.80. Found: C, 
52.21; H, 8.15; N, 8.46. 
EXAMPLE 16 
(Boc-amino)ethylglycine Methyl Ester, 20 
A. Reduction With Sodium Cyanoborohydride 
Boc-aminoacetaldehyde (19, 1.00 g, 6.3 mmol, 1 eqv) 
Was dissolved in methanol (50 ml). Anhydrous sodium 
acetate (1.03 g, 12.6 mmol, 2 eqv), glycine methyl ester 
hydrochloride (Aldrich Chemical Co., 0.79 g, 6.3 mmol, 1 
eqv) and sodium cyanoborohydride (1.97 g, 31.4 mmol, 5 
eqv) Were added to the solution in that order. The reaction 
mixture Was stirred for 2 h at room temperature under 
nitrogen. Water (50 ml) Was added to the suspension and the 
resulting clear solution Was evaporated under reduced pres 
sure to remove the methanol. The aqueous phase Was 
extracted With methylene chloride (3x100 ml). The organic 
phase Was Washed With a saturated aqueous solution of 
sodium chloride (1><100 ml), dried (Na2SO4), ?ltered and 
then evaporated under reduced pressure affording 1.41 g of 
crude title compound as a yelloW oil. The crude product Was 
kugelrohr distilled at 110° C. and 0.5 mbar to yield 0.49 g 
(34%) of 2-(Boc-amino)ethylglycine methyl ester as a col 
orless liquid. 1H-NMR (CDCl3/TMS) : 6=1.36 (s, 9H, 
Me3C), 1.91 (s, 1H, NH), 2.67 (t, J=6 HZ, 2H, NHCH2), 3.13 
(q, J=6 HZ, 2H, NHCH2), 3.34 (s, 2H, CHZCOO), 3.65 (s, 
3H, OMe), 5.13 (b, 1H, carbamate NH). 13C-NMR (CDCl3/ 
TMS): 6=28.2 (Me3C), 39.9, 48.5 (NHCH2), 50.0 
(CHZCOO), 51.5 (OMe), 78.9 (Me3C), 155.9 (carbamate 
C=O), 172.6 (ester C=O). Anal. Calcd for C1OH2N2O4: C, 
51.71; H, 8.68; N, 12.06. Found: C, 51.55; H, 8.72; N, 11.79. 
B. Catalytic hydrogenation 
Boc-aminoacetaldehyde (2.08 g, 13.1 mmol, 1 eqv) Was 
dissolved in methanol (50 ml) and cooled to 00 C. Palladium 
on activated carbon (10%, 0.4 g) Was added under nitrogen 
and With vigorous stirring. Anhydrous sodium acetate (2.14 
g, 26.1 mmol, 2 eqv) and glycine methyl ester, hydrochlo 
ride (1.64 g, 13.1 mmol, 1 eqv) each dissolved in methanol 
(25 ml) Were added to the mixture. The reaction mixture Was 
hydrogenated at atmospheric pressure and room temperature 
With vigorous stirring, until hydrogen uptake had ceased 
(When 287 ml, 13.1 mmol, 1 eqv had been consumed) after 
about 1 h. The reaction mixture Was ?ltered and the solvent 
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removed under reduced pressure. The residue Was sus 
pended in Water (30 ml), and during vigorous stirring pH 
Was adjusted to 8 by dropWise addition of 0.5N NaOH. The 
Water phase Was extracted With methylene chloride (4x50 
ml). The organic phase Was dried (Na2SO4), ?ltered and 
evaporated under reduced pressure to yield 3.03 g of crude 
title compound as a golden oil. The crude product Was 
kugelrohr distilled at 100° C and 0.2 mbar to afford 2.33 g 
(77%) of 2-(Boc-amino)ethylglycine methyl ester as a col 
orless liquid. The analytical data Were in accord With those 
provided above for the reduction With sodium cyanoboro 
hydride. 
EXAMPLE 17 
General Method for the Synthesis of PNA 
Oligomers 
Oligomers Were prepared generally in accordance With 
the methods disclosed by WO 92/20702. BenZyhydrylamine 
resin (initially loaded 0.28 mmol/gm With Boc-L-Lys 
(2-chlorobenyloxycarbonyl)) Was sWollen in DMF and an 
excess of a monomer to be coupled Was added, folloWed by 
dicyclohexyl-carbodiimide (0.15M in 50% DMF in 
dichloromethane). The Boc deprotection Was accomplished 
by tri?uoroacetic acid treatment. The progress of the cou 
pling reactions Was monitored by quantitative ninhydrin 
analysis. The PNA Was released from the resin using anhy 
drous HF under standard conditions. The products Were 
puri?ed using HPLC With acetonitrile-Water (0.1%TFA) 
gradient and structure con?rmed by fast atom bombardment 
mass spectrometry. The folloWing sequences have been 
synthesized by this method: 
H-TloLysNH2 (SEQ ID NO: 1) 
H-T4CT5LysNH2 (SEQ ID NO: 2) 
H-T2CT2CT4LysNH2 (SEQ ID NO: 3) 
H-T4CT2CT2LysNH2 (SEQ ID NO: 4) 
H-TGTACGTCACAACTA-NH2 (SEQ ID NO: 5) 
H-CCTTCCCTT-NH2 (SEQ ID NO: 6) 
H-TTCCCTTCC-NH2 (SEQ ID NO: 7) 
H-TAGTTATCTCTATCT-NH2 (SEQ ID NO: 8) 
H-TGTACGTCACAACTA-NH2 (SEQ ID NO: 9) 
H-GCACAGCC-LYS-NH2 (SEQ ID NO: 10) 
H-TTTTCTTTT-NH2 (SEQ ID NO: 110 
H-TTTTTTTTTCCCCCCC-NH2 (SEQ ID NO: 12) 
H-CCCCCCCTTTTTTTTT-NH2 (SEQ ID NO: 13) 
H-CCTCCTTCCC-NH2 (SEQ ID NO: 14) 
H-TTCTCTCTCT-NH2 (SEQ ID NO: 15) 
H-TTTTTCTCTCTCTCT-NH2 (SEQ ID NO: 16) 
H-CCCCCACCACTTCCCCTCTC-(Lys)9NH2 (SEQ ID 
NO: 17) 
H-CTTATATTCCGTCATCGCTCLys-NH2 (SEQ ID NO: 
18) 
H-CTGTCTCCATCCTCTTCACT-NH2 (SEQ ID NO: 19) 
H-TATTCCGTCATCGCTCCTCALys-NH2 (SEQ ID NO: 
20) 
H-CCCCCACCACTTCCCCTCTC-NH2 (SEQ ID NO: 21) 
H-CTGCTGCCTCTGTCTCAGGTLysNH2 (SEQ ID NO: 
22) 
H-T4-([3-alanine) C-TSLysNH2 (SEQ ID NO: 23) 
H-T4-([3-alanine) T-TSLysNH2 (SEQ ID NO: 24) 
Those skilled in the art Will appreciate that numerous 
changes and modi?cations may be made to the preferred 
embodiments of the invention and that such changes and 
modi?cations may be made Without departing from the spirit 
of the invention. It is therefore intended that the appended 
claims cover all such equivalent variations as fall Within the 
true spirit and scope of the invention. 
5,773,571 
15 16 
SEQUENCE LISTING 
( 1 ) GENERAL INFORMATION: 
( i i i )NUMBER OF SEQUENCES: 24 
( 2 ) INFORMATION FOR SEQ ID NO:1: 
( i )SEQUENCE CHARACTERISTICS: 
( A ) LENGTH: 11 amino acids 
( B )TYPE: amino acid 
( c )STRANDEDNESS: single 
( D )TOPOLOGY: unknown 
( i i )MOLECULE TYPE: peptide 
( i X ) FEATURE: 
( A ) NAIVEE/KEY: Modi?ed-site 
( B ) LOCATION: 1 
( D ) OTHER INFORMATION: /label=MODIFIED-SITE 
/ note= “Thymine heterocycle is attached to 
N-acetyl(2- aminoethyl)glycine through the 
N-acetyl group at position 1 of the heterocycle.’7 
( i X ) FEATURE: 
( A ) NAIVEE/KEY: Modi?ed-site 
( B ) LOCATION: 2 
( D ) OTHER INFORMATION: /label=Modi?ed-site 
/ note= “Thymine heterocycle is attached to 
N-acetyl(2- aminoethyl)glycine through the N-acetyl 
group at position 1 of the heterocycle.’7 
( i X ) FEATURE: 
( A ) NAIVEE/KEY: Modi?ed-site 
( B ) LOCATION: 3 
( D ) OTHER INFORMATION: /label=Modi?ed-site 
/ note= “Thymine heterocycle is attached to 
N-acetyl(2- aminoethyl)glycine through the N-acetyl 
group at position 1 of the heterocycle.’7 
( i X ) FEATURE: 
( A ) NAIVEE/KEY: Modi?ed-site 
( B ) LOCATION: 4 
( D ) OTHER INFORMATION: /label=Modi?ed-site 
/ note= “Thymine heterocycle is attached to 
N-acetyl(2- aminoethyl)glycine through the N-acetyl 
group at position 1 of the heterocycle.’7 
( i X ) FEATURE: 
( A ) NAIVEE/KEY: Modi?ed-site 
( B ) LOCATION: 5 
( D ) OTHER INFORMATION: /label=Modi?ed-site 
/ note= “Thymine heterocycle is attached to 
N-acetyl(2- aminoethyl)glycine through the N-acetyl 
group at position 1 of the heterocycle.’7 
( i X ) FEATURE: 
( A ) NAIVEE/KEY: Modi?ed-site 
( B ) LOCATION: 6 
( D ) OTHER INFORMATION: /label=Modi?ed-site 
/ note= “Thymine heterocycle is attached to 
N-acetyl(2- aminoethyl)glycine through the N-acetyl 
group at position 1 of the heterocycle.’7 
( i X ) FEATURE: 
( A ) NAIVEE/KEY: Modi?ed-site 
( B ) LOCATION: 7 
( D ) OTHER INFORMATION: /label=Modi?ed-site 
/ note= “Thymine heterocycle is attached to 
N-acetyl(2- aminoethyl)glycine through the N-acetyl 
group at position 1 of the heterocycle.’7 
( i X ) FEATURE: 
( A ) NAIVEE/KEY: Modi?ed-site 
( B ) LOCATION: 8 
( D ) OTHER INFORMATION: /label=Modi?ed-site 
/ note= “Thymine heterocycle is attached to 
N-acetyl(2- aminoethyl)glycine through the N-acetyl 
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group at position 1 of the heterocycle.’7 
( i X ) FEATURE: 
( A ) NAIVEE/KEY: Modi?ed-site 
( B ) LOCATION: 9 
( D ) OTHER INFORMATION: /label=Modi?ed-site 
/ note= “Thymine heterocycle is attached to 
N-acetyl(2- aminoethyl)glycine through the N-acetyl 
group at position 1 of the heterocycle.’7 
( i X ) FEATURE: 
( A ) NAIVEE/KEY: Modi?ed-site 
( B ) LOCATION: 10 
( D ) OTHER INFORMATION: /label=Modi?ed-site 
/ note= “Thymine heterocycle is attached to 
N-acetyl(2- aminoethyl)glycine through the N-acetyl 
group at position 1 of the heterocycle.’7 
( X i ) SEQUENCE DESCRIPTION: SEQ ID NO:1: 
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Lys 
1 5 1O 
( 2 ) INFORMATION FOR SEQ ID NO:2: 
( i )SEQUENCE CHARACTERISTICS: 
( A ) LENGTH: 11 amino acids 
( B )TYPE: amino acid 
( c )STRANDEDNESS: single 
( D )TOPOLOGY: unknown 
( i i )MOLECULE TYPE: peptide 
( i X ) FEATURE: 
( A ) NAIVEE/KEY: Modi?ed-site 
( B ) LOCATION: 1 
( D ) OTHER INFORMATION: /label=Modi?ed-site 
/ note= “Thymine heterocycle is attached to 
N-acetyl(2- aminoethyl)glycine through the N-acetyl 
group at position 1 of the heterocycle.’7 
( i X ) FEATURE: 
( A ) NAIVEE/KEY: Modi?ed-site 
( B ) LOCATION: 2 
( D ) OTHER INFORMATION: /label=Modi?ed-site 
/ note= “Thymine heterocycle is attached to 
N-acetyl(2- aminoethyl)glycine through the N-acetyl 
group at position 1 of the heterocycle.’7 
( i X ) FEATURE: 
( A ) NAIVEE/KEY: Modi?ed-site 
( B ) LOCATION: 3 
( D ) OTHER INFORMATION: /label=Modi?ed-site 
/ note= “Thymine heterocycle is attached to 
N-acetyl(2- aminoethyl)glycine through the N-acetyl 
group at position 1 of the heterocycle.’7 
( i X ) FEATURE: 
( A ) NAIVEE/KEY: Modi?ed-site 
( B ) LOCATION: 4 
( D ) OTHER INFORMATION: /label=Modi?ed-site 
/ note= “Thymine heterocycle is attached to 
N-acetyl(2- aminoethyl)glycine through the N-acetyl 
group at position 1 of the heterocycle.’7 
( i X ) FEATURE: 
( A ) NAIVEE/KEY: Modi?ed-site 
( B ) LOCATION: 5 
( D ) OTHER INFORMATION: /label=Modi?ed-site 
/ note= “Cytosine heterocycle is attached to 
N-acetyl(2- aminoethyl)glycine through the N-acetyl 
group at postion 1 of the heterocycle.’7 
( i X ) FEATURE: 
( A ) NAIVEE/KEY: Modi?ed-site 
( B ) LOCATION: 6 
( D ) OTHER INFORMATION: /label=Modi?ed-site 
/ note= “Thymine heterocycle is attached to 
N-acetyl(2- aminoethyl)glycine through the N-acetyl 
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group at position 1 of the heterocycle.’7 
i X ) FEATURE: 
( A ) NAIVEE/KEY: Modi?ed-site 
( B ) LOCATION: 7 
( D ) OTHER INFORMATION: /label=Modi?ed-site 
/ note= “Thymine heterocycle is attached to 
N-acetyl(2- aminoethyl)glycine through the N-acetyl 
group at position 1 of the heterocycle.’7 
i X ) FEATURE: 
( A ) NAIVEE/KEY: Modi?ed-site 
( B ) LOCATION: 8 
( D ) OTHER INFORMATION: /label=Modi?ed-site 
/ note= “Thymine heterocycle is attached to 
N-acetyl(2- aminoethyl)glycine through the N-acetyl 
group at position 1 of the heterocycle.’7 
i X ) FEATURE: 
( A ) NAIVEE/KEY: Modi?ed-site 
( B ) LOCATION: 9 
( D ) OTHER INFORMATION: /label=Modi?ed-site 
/ note= “Thymine heterocycle is attached to 
N-acetyl(2- aminoethyl)glycine through the N-acetyl 
group at position 1 of the heterocycle.’7 
i X ) FEATURE: 
( A ) NAIVEE/KEY: Modi?ed-site 
( B ) LOCATION: 10 
( D ) OTHER INFORMATION: /label=Modi?ed-site 
/ note= “Thymine heterocycle is attached to 
N-acetyl(2- aminoethyl)glycine through the N-acetyl 
group at position 1 of the heterocycle.’7 
X i ) SEQUENCE DESCRIPTION: SEQ ID NO:2: 
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Lys 
1 5 1 O 
( 2 ) INFORMATION FOR SEQ ID NO:3: 
( i )SEQUENCE CHARACTERISTICS: 
( A ) LENGTH: 11 amino acids 
( B )TYPE: amino acid 
( c )STRANDEDNESS: single 
( D )TOPOLOGY: unknown 
i i )MOLECULE TYPE: peptide 
i X ) FEATURE: 
( A ) NAIVEE/KEY: Modi?ed-site 
( B ) LOCATION: 1 
( D ) OTHER INFORMATION: /label=Modi?ed-site 
/ note= “Thymine heterocycle is attached to 
N-acetyl(2- aminoethyl)glycine through the N-acetyl 
group at position 1 of the heterocycle.’7 
i X ) FEATURE: 
( A ) NAIVEE/KEY: Modi?ed-site 
( B ) LOCATION: 2 
( D ) OTHER INFORMATION: /label=Modi?ed-site 
/ note= “Thymine heterocycle is attached to 
N-acetyl(2- aminoethyl)glycine through the N-acetyl 
group at position 1 of the heterocycle.’7 
i X ) FEATURE: 
( A ) NAIVEE/KEY: Modi?ed-site 
( B ) LOCATION: 3 
( D ) OTHER INFORMATION: /label=Modi?ed-site 
/ note= “Cytosine heterocycle is attached to 
N-acetyl(2- aminoethyl)glycine through the N-acetyl 
group at position 1 of the heterocycle.’7 
i X ) FEATURE: 
( A ) NAIVEE/KEY: Modi?ed-site 
( B ) LOCATION: 4 
( D ) OTHER INFORMATION: /label=Modi?ed-site 
/ note= “Thymine heterocycle is attached to 
N-acetyl(2- aminoethyl)glycine through the N-acetyl 
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group at position 1 of the heterocycle.’7 
A i X ) FEATURE: 
( A ) NAIVEE/KEY: Modi?ed-site 
( B ) LOCATION: 5 
( D ) OTHER INFORMATION: /label=Modi?ed-site 
/ note= “Thymine heterocycle is attached to 
N-acetyl(2- aminoethyl)glycine through the N-acetyl 
group at position 1 of the heterocycle.’7 
A i X ) FEATURE: 
( A ) NAIVEE/KEY: Modi?ed-site 
( B ) LOCATION: 6 
( D ) OTHER INFORMATION: /label=Modi?ed-site 
/ note= “Cytosine heterocycle is attached to 
N-acetyl(2- aminoethyl)glycine through the N-acetyl 
group at position 1 of the heterocycle.’7 
A i X ) FEATURE: 
( A ) NAIVEE/KEY: Modi?ed-site 
( B ) LOCATION: 7 
( D ) OTHER INFORMATION: /label=Modi?ed-site 
/ note= “Thymine heterocycle is attached to 
N-acetyl(2- aminoethyl)glycine through the N-acetyl 
group at position 1 of the heterocycle.’7 
A i X ) FEATURE: 
( A ) NAIVEE/KEY: Modi?ed-site 
( B ) LOCATION: 8 
( D ) OTHER INFORMATION: /label=Modi?ed-site 
/ note= “Thymine heterocycle is attached to 
N-acetyl(2- aminoethyl)glycine through the N-acetyl 
group at position 1 of the heterocycle.’7 
A i X ) FEATURE: 
( A ) NAIVEE/KEY: Modi?ed-site 
( B ) LOCATION: 9 
( D ) OTHER INFORMATION: /label=Modi?ed-site 
/ note= “Thymine heterocycle is attached to 
N-acetyl(2- aminoethyl)glycine through the N-acetyl 
group at position 1 of the heterocycle.’7 
A i X ) FEATURE: 
( A ) NAIVEE/KEY: Modi?ed-site 
( B ) LOCATION: 10 
( D ) OTHER INFORMATION: /label=Modi?ed-site 
/ note= “Thymine heterocycle is attached to 
N-acetyl(2- aminoethyl)glycine through the N-acetyl 
group at position 1 of the heterocycle.’7 
A X i ) SEQUENCE DESCRIPTION: SEQ ID NO:3: 
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Lys 
1 5 1O 
( 2 ) INFORMATION FOR SEQ ID NO:4: 
( i )SEQUENCE CHARACTERISTICS: 
( A ) LENGTH: 11 amino acids 
( B )TYPE: amino acid 
( c )STRANDEDNESS: single 
( D )TOPOLOGY: unknown 
( i i )MOLECULE TYPE: peptide 
( i X ) FEATURE: 
( A ) NAIVEE/KEY: Modi?ed-site 
( B ) LOCATION: 1 
( D ) OTHER INFORMATION: /label=Modi?ed-site 
/ note= “Thymine heterocycle is attached to 
N-acetyl(2- aminoethyl)glycine through the N-acetyl 
group at position 1 of the heterocycle.’7 
( i X ) FEATURE: 
( A ) NAIVEE/KEY: Modi?ed-site 
( B ) LOCATION: 2 
( D ) OTHER INFORMATION: /label=Modi?ed-site 
/ note= “Thymine heterocycle is attached to 
N-acetyl(2- aminoethyl)glycine through the N-acetyl 
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group at position 1 of the heterocycle.’7 
i X ) FEATURE: 
( A ) NAIVEE/KEY: Modi?ed-site 
( B ) LOCATION: 3 
( D ) OTHER INFORMATION: /label=Modi?ed-site 
/ note= “Thymine heterocycle is attached to 
N-acetyl(2- aminoethyl)glycine through the N-acetyl 
group at position 1 of the heterocycle.’7 
i X ) FEATURE: 
( A ) NAIVEE/KEY: Modi?ed-site 
( B ) LOCATION: 4 
( D ) OTHER INFORMATION: /label=Modi?ed-site 
/ note= “Thymine heterocycle is attached to 
N-acetyl(2- aminoethyl)glycine through the N-acetyl 
group at position 1 of the heterocycle.’7 
i X ) FEATURE: 
( A ) NAIVEE/KEY: Modi?ed-site 
( B ) LOCATION: 5 
( D ) OTHER INFORMATION: /label=Modi?ed-site 
/ note= “Cytosine heterocycle is attached to 
N-acetyl(2- aminoethyl)glycine through the N-acetyl 
group at position 1 of the heterocycle.’7 
i X ) FEATURE: 
( A ) NAIVEE/KEY: Modi?ed-site 
( B ) LOCATION: 6 
( D ) OTHER INFORMATION: /label=Modi?ed-site 
/ note= “Thymine heterocycle is attached to 
N-acetyl(2- aminoethyl)glycine through the N-acetyl 
group at position 1 of the heterocycle.’7 
i X ) FEATURE: 
( A ) NAIVEE/KEY: Modi?ed-site 
( B ) LOCATION: 7 
( D ) OTHER INFORMATION: /label=Modi?ed-site 
/ note= “Thymine heterocycle is attached to 
N-acetyl(2- aminoethyl)glycine through the N-acetyl 
group at position 1 of the heterocycle.’7 
i X ) FEATURE: 
( A ) NAIVEE/KEY: Modi?ed-site 
( B ) LOCATION: 8 
( D ) OTHER INFORMATION: /label=Modi?ed-site 
/ note= “Cytosine heterocycle is attached to 
N-acetyl(2- aminoethyl)glycine through the N-acetyl 
group at position 1 of the heterocycle.’7 
i X ) FEATURE: 
( A ) NAIVEE/KEY: Modi?ed-site 
( B ) LOCATION: 9 
( D ) OTHER INFORMATION: /label=Modi?ed-site 
/ note= “Thymine heterocycle is attached to 
N-acetyl(2- aminoethyl)glycine through the N-acetyl 
group at position 1 of the heterocycle.’7 
i X ) FEATURE: 
( A ) NAIVEE/KEY: Modi?ed-site 
( B ) LOCATION: 10 
( D ) OTHER INFORMATION: /label=Modi?ed-site 
/ note= “Thymine heterocycle is attached to 
N-acetyl(2- aminoethyl)glycine through the N-acetyl 
group at position 1 of the heterocycle.’7 
X i ) SEQUENCE DESCRIPTION: SEQ ID NO:4: 
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Lys 
1 5 1 O 
( 2 ) INFORMATION FOR SEQ ID NO:5: 
( i )SEQUENCE CHARACTERISTICS: 
( A ) LENGTH: 15 amino acids 
( B )TYPE: amino acid 
( c )STRANDEDNESS: single 
( D )TOPOLOGY: unknown 
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i ) MOLECULE TYPE: peptide 
X ) FEATURE: 
( A ) NAIVEE/KEY: Modi?ed-site 
( B ) LOCATION: 1 
( D ) OTHER INFORMATION: /label=Modi?ed-site 
/ note= “Thymine heterocycle is attached to 
N-acetyl(2- aminoethyl)glycine through the N-acetyl 
group at position 1 of the heterocycle.’7 
X ) FEATURE: 
( A ) NAIVEE/KEY: Modi?ed-site 
( B ) LOCATION: 2 
( D ) OTHER INFORMATION: /label=Modi?ed-site 
/ note= “Guanine heterocycle is attached to 
N-acetyl(2- aminoethyl)glycine through the N-acetyl 
group at position 9 of the heterocycle.’7 
X ) FEATURE: 
( A ) NAIVEE/KEY: Modi?ed-site 
( B ) LOCATION: 3 
( D ) OTHER INFORMATION: /label=Modi?ed-site 
/ note= “Thymine heterocycle is attached to 
N-acetyl(2- aminoethyl)glycine through the N-acetyl 
group at position 1 of the heterocycle.’7 
X ) FEATURE: 
( A ) NAIVEE/KEY: Modi?ed-site 
( B ) LOCATION: 4 
( D ) OTHER INFORMATION: /label=Modi?ed-site 
/ note= “Adenine heterocycle is attached to 
N-acetyl(2- aminoethyl)glycine through the N-acetyl 
group at position 9 of the heterocycle.’7 
X ) FEATURE: 
( A ) NAIVEE/KEY: Modi?ed-site 
( B ) LOCATION: 5 
( D ) OTHER INFORMATION: /label=Modi?ed-site 
/ note= “Cytosine heterocycle is attached to 
N-acetyl(2- aminoethyl)glycine through the N-acetyl 
group at position 1 of the heterocycle.’7 
X ) FEATURE: 
( A ) NAIVEE/KEY: Modi?ed-site 
( B ) LOCATION: 6 
( D ) OTHER INFORMATION: /label=Modi?ed-site 
/ note= “Guanine heterocycle is attached to 
N-acetyl(2- aminoethyl)glycine through the N-acetyl 
group at position 9 of the heterocycle.’7 
X ) FEATURE: 
( A ) NAIVEE/KEY: Modi?ed-site 
( B ) LOCATION: 7 
( D ) OTHER INFORMATION: /label=Modi?ed-site 
/ note= “Thymine heterocycle is attached to 
N-acetyl(2- aminoethyl)glycine through the N-acetyl 
group at position 1 of the heterocycle.’7 
X ) FEATURE: 
( A ) NAIVEE/KEY: Modi?ed-site 
( B ) LOCATION: 8 
( D ) OTHER INFORMATION: /label=Modi?ed-site 
/ note= “Cytosine heterocycle is attached to 
N-acetyl(2- aminoethyl)glycine through the N-acetyl 
group at position 1 of the heterocycle.’7 
X ) FEATURE: 
( A ) NAIVEE/KEY: Modi?ed-site 
( B ) LOCATION: 9 
( D ) OTHER INFORMATION: /label=Modi?ed-site 
/ note= “Adenine heterocycle is attached to 
N-acetyl(2- aminoethyl)glycine through the N-acetyl 
group at position 9 of the heterocycle.’7 
X ) FEATURE: 
( A ) NAIVEE/KEY: Modi?ed-site 
( B ) LOCATION: 10 
( D ) OTHER INFORMATION: /label=Modi?ed-site 
/ note= “Cytosine heterocycle is attached to 
N-acetyl(2- aminoethyl)glycine through the N-acetyl 
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group at position 1 of the heterocycle.’7 
A i X ) FEATURE: 
( A ) NAIVEE/KEY: Modi?ed-site 
( B ) LOCATION: 11 
( D ) OTHER INFORMATION: /label=Modi?ed-site 
/ note= “Adenine heterocycle is attached to 
N-acetyl(2- aminoethyl)glycine through the N-acetyl 
group at position 9 of the heterocycle.’7 
A i X ) FEATURE: 
( A ) NAIVEE/KEY: Modi?ed-site 
( B ) LOCATION: 12 
( D ) OTHER INFORMATION: /label=Modi?ed-site 
/ note= “Adenine heterocycle is attached to 
N-acetyl(2- aminoethyl)glycine through the N-acetyl 
group at position 9 of the heterocycle.’7 
A i X ) FEATURE: 
( A ) NAIVEE/KEY: Modi?ed-site 
( B ) LOCATION: 13 
( D ) OTHER INFORMATION: /label=Modi?ed-site 
/ note= “Cytosine heterocycle is attached to 
N-acetyl(2- aminoethyl)glycine through the N-acetyl 
group at position 1 of the heterocycle.’7 
A i X ) FEATURE: 
( A ) NAIVEE/KEY: Modi?ed-site 
( B ) LOCATION: 14 
( D ) OTHER INFORMATION: /label=Modi?ed-site 
/ note= “Thymine heterocycle is attached to 
N-acetyl(2- aminoethyl)glycine through the N-acetyl 
group at position 1 of the heterocycle.’7 
A i X ) FEATURE: 
( A ) NAIVEE/KEY: Modi?ed-site 
( B ) LOCATION: 15 
( D ) OTHER INFORMATION: /label=Modi?ed-site 
/ note= “Adenine heterocycle is attached to 
N-acetyl(2- aminoethyl)glycine through the N-acetyl 
group at position 9 of the heterocycle.’7 
A X i ) SEQUENCE DESCRIPTION: SEQ ID NO:5: 
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 
1 5 1O 15 
( 2 ) INFORMATION FOR SEQ ID NO:6: 
( i )SEQUENCE CHARACTERISTICS: 
( A ) LENGTH: 9 amino acids 
( B )TYPE: amino acid 
( c )STRANDEDNESS: single 
( D )TOPOLOGY: unknown 
( i i )MOLECULE TYPE: peptide 
( i X ) FEATURE: 
( A ) NAIVEE/KEY: Modi?ed-site 
( B ) LOCATION: 1 
( D ) OTHER INFORMATION: /label=Modi?ed-site 
/ note= “Cytosine heterocycle is attached to 
N-acetyl(2- aminoethyl)glycine through the N-acetyl 
group at position 1 of the heterocycle.’7 
( i X ) FEATURE: 
( A ) NAIVEE/KEY: Modi?ed-site 
( B ) LOCATION: 2 
( D ) OTHER INFORMATION: /label=Modi?ed-site 
/ note= “Cytosine heterocycle is attached to 
N-acetyl(2- aminoethyl)glycine through the N-acetyl 
group at position 1 of the heterocycle.’7 
( i X ) FEATURE: 
( A ) NAIVEE/KEY: Modi?ed-site 
( B ) LOCATION: 3 
( D ) OTHER INFORMATION: /label=Modi?ed-site 
/ note= “Thymine heterocycle is attached to 
N-acetyl(2- aminoethyl)glycine through the N-acetyl 
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group at position 1 of the heterocycle.’7 
A i X ) FEATURE: 
( A ) NAIVEE/KEY: Modi?ed-site 
( B ) LOCATION: 4 
( D ) OTHER INFORMATION: /label=Modi?ed-site 
/ note= “Thymine heterocycle is attached to 
N-acetyl(2- aminoethyl)glycine through the N-acetyl 
group at position 1 of the heterocycle.’7 
A i X ) FEATURE: 
( A ) NAIVEE/KEY: Modi?ed-site 
( B ) LOCATION: 5 
( D ) OTHER INFORMATION: /label=Modi?ed-site 
/ note= “Cytosine heterocycle is attached to 
N-acetyl(2- aminoethyl)glycine through the N-acetyl 
group at position 1 of the heterocycle.’7 
A i X ) FEATURE: 
( A ) NAIVEE/KEY: Modi?ed-site 
( B ) LOCATION: 6 
( D ) OTHER INFORMATION: /label=Modi?ed-site 
/ note= “Cytosine heterocycle is attached to 
N-acetyl(2- aminoethyl)glycine through the N-acetyl 
group at position 1 of the heterocycle.’7 
A i X ) FEATURE: 
( A ) NAIVEE/KEY: Modi?ed-site 
( B ) LOCATION: 7 
( D ) OTHER INFORMATION: /label=Modi?ed-site 
/ note= “Cytosine heterocycle is attached to 
N-acetyl(2- aminoethyl)glycine through the N-acetyl 
group at position 1 of the heterocycle.’7 
A i X ) FEATURE: 
( A ) NAIVEE/KEY: Modi?ed-site 
( B ) LOCATION: 8 
( D ) OTHER INFORMATION: /label=Modi?ed-site 
/ note= “Thymine heterocycle is attached to 
N-acetyl(2- aminoethyl)glycine through the N-acetyl 
group at position 1 of the heterocycle.’7 
A i X ) FEATURE: 
( A ) NAIVEE/KEY: Modi?ed-site 
( B ) LOCATION: 9 
( D ) OTHER INFORMATION: /label=Modi?ed-site 
/ note= “Thymine heterocycle is attached to 
N-acetyl(2- aminoethyl)glycine through the N-acetyl 
group at position 1 of the heterocycle.’7 
A X i ) SEQUENCE DESCRIPTION: SEQ ID NO:6: 
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 
1 5 
( 2 ) INFORMATION FOR SEQ ID NO:7: 
( i )SEQUENCE CHARACTERISTICS: 
( A ) LENGTH: 9 amino acids 
( B )TYPE: amino acid 
( c )STRANDEDNESS: single 
( D )TOPOLOGY: unknown 
( i i )MOLECULE TYPE: peptide 
( i X ) FEATURE: 
( A ) NAIVEE/KEY: Modi?ed-site 
( B ) LOCATION: 1 
( D ) OTHER INFORMATION: /label=Modi?ed-site 
/ note= “Thymine heterocycle is attached to 
N-acetyl(2- aminoethyl)glycine through the N-acetyl 
group at position 1 of the heterocycle.’7 
( i X ) FEATURE: 
( A ) NAIVEE/KEY: Modi?ed-site 
( B ) LOCATION: 2 
( D ) OTHER INFORMATION: /label=Modi?ed-site 
/ note= “Thymine heterocycle is attached to 
N-acetyl(2- aminoethyl)glycine through the N-acetyl 
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group at position 1 of the heterocycle.’7 
A i X ) FEATURE: 
( A ) NAIVEE/KEY: Modi?ed-site 
( B ) LOCATION: 3 
( D ) OTHER INFORMATION: /label=Modi?ed-site 
/ note= “Cytosine heterocycle is attached to 
N-acetyl(2- aminoethyl)glycine through the N-acetyl 
group at position 1 of the heterocycle.’7 
A i X ) FEATURE: 
( A ) NAIVEE/KEY: Modi?ed-site 
( B ) LOCATION: 4 
( D ) OTHER INFORMATION: /label=Modi?ed-site 
/ note= “Cytosine heterocycle is attached to 
N-acetyl(2- aminoethyl)glycine through the N-acetyl 
group at position 1 of the heterocycle.’7 
A i X ) FEATURE: 
( A ) NAIVEE/KEY: Modi?ed-site 
( B ) LOCATION: 5 
( D ) OTHER INFORMATION: /label=Modi?ed-site 
/ note= “Cytosine heterocycle is attached to 
N-acetyl(2- aminoethyl)glycine through the N-acetyl 
group at position 1 of the heterocycle.’7 
A i X ) FEATURE: 
( A ) NAIVEE/KEY: Modi?ed-site 
( B ) LOCATION: 6 
( D ) OTHER INFORMATION: /label=Modi?ed-site 
/ note= “Thymine heterocycle is attached to 
N-acetyl(2- aminoethyl)glycine through the N-acetyl 
group at position 1 of the heterocycle.’7 
A i X ) FEATURE: 
( A ) NAIVEE/KEY: Modi?ed-site 
( B ) LOCATION: 7 
( D ) OTHER INFORMATION: /label=Modi?ed-site 
/ note= “Thymine heterocycle is attached to 
N-acetyl(2- aminoethyl)glycine through the N-acetyl 
group at position 1 of the heterocycle.’7 
A i X ) FEATURE: 
( A ) NAIVEE/KEY: Modi?ed-site 
( B ) LOCATION: 8 
( D ) OTHER INFORMATION: /label=Modi?ed-site 
/ note= “Cytosine heterocycle is attached to 
N-acetyl(2- aminoethyl)glycine through the N-acetyl 
group at position 1 of the heterocycle.’7 
A i X ) FEATURE: 
( A ) NAIVEE/KEY: Modi?ed-site 
( B ) LOCATION: 9 
( D ) OTHER INFORMATION: /label=Modi?ed-site 
/ note= “Cytosine heterocycle is attached to 
N-acetyl(2- aminoethyl)glycine through the N-acetyl 
group at position 1 of the heterocycle.’7 
A X i ) SEQUENCE DESCRIPTION: SEQ ID NO:7: 
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 
1 5 
( 2 ) INFORMATION FOR SEQ ID NO:8: 
( i )SEQUENCE CHARACTERISTICS: 
( A ) LENGTH: 15 amino acids 
( B )TYPE: amino acid 
( c )STRANDEDNESS: single 
( D )TOPOLOGY: unknown 
( i i )MOLECULE TYPE: peptide 
( i X ) FEATURE: 
( A ) NAIVEE/KEY: Modi?ed-site 
( B ) LOCATION: 1 
( D ) OTHER INFORMATION: /label=Modi?ed-site 
/ note= “Thymine heterocycle is attached to 
N-acetyl(2- aminoethyl)glycine through the N-acetyl 
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group at position 1 of the heterocycle.’7 
X ) FEATURE: 
( A ) NAIVEE/KEY: Modi?ed-site 
( B ) LOCATION: 2 
( D ) OTHER INFORMATION: /label=Modi?ed-site 
/ note= “Adenine heterocycle is attached to 
N-acetyl(2- aminoethyl)glycine through the N-acetyl 
group at position 9 of the heterocycle.’7 
X ) FEATURE: 
( A ) NAIVEE/KEY: Modi?ed-site 
( B ) LOCATION: 3 
( D ) OTHER INFORMATION: /label=Modi?ed-site 
/ note= “Guanine heterocycle is attached to 
N-acetyl(2- aminoethyl)glycine through the N-acetyl 
group at position 9 of the heterocycle.’7 
X ) FEATURE: 
( A ) NAIVEE/KEY: Modi?ed-site 
( B ) LOCATION: 4 
( D ) OTHER INFORMATION: /label=Modi?ed-site 
/ note= “Thymine heterocycle is attached to 
N-acetyl(2- aminoethyl)glycine through the N-acetyl 
group at position 1 of the heterocycle.’7 
X ) FEATURE: 
( A ) NAIVEE/KEY: Modi?ed-site 
( B ) LOCATION: 5 
( D ) OTHER INFORMATION: /label=Modi?ed-site 
/ note= “Thymine heterocycle is attached to 
N-acety(2- aminoethyl)glycine through the N-acetyl 
group at position 1 of the heterocycle.’7 
X ) FEATURE: 
( A ) NAIVEE/KEY: Modi?ed-site 
( B ) LOCATION: 6 
( D ) OTHER INFORMATION: /label=Modi?ed-site 
/ note= “Adenine heterocycle is attached to 
N-acetyl(2- aminoethyl)glycine through the N-acetyl 
group at position 9 of the heterocycle.’7 
X ) FEATURE: 
( A ) NAIVEE/KEY: Modi?ed-site 
( B ) LOCATION: 7 
( D ) OTHER INFORMATION: /label=Modi?ed-site 
/ note= “Thymine heterocycle is attached to 
N-acetyl(2- aminoethyl)glycine through the N-acetyl 
group at position 1 of the heterocycle.’7 
X ) FEATURE: 
( A ) NAIVEE/KEY: Modi?ed-site 
( B ) LOCATION: 8 
( D ) OTHER INFORMATION: /label=Modi?ed-site 
/ note= “Cytosine heterocycle is attached to 
N-acetyl(2- aminoethyl)glycine through the N-acetyl 
group at position 1 of the heterocycle.’7 
X ) FEATURE: 
( A ) NAIVEE/KEY: Modi?ed-site 
( B ) LOCATION: 9 
( D ) OTHER INFORMATION: /label=Modi?ed-site 
/ note= “Thymine heterocycle is attached to 
N-acetyl(2- aminoethyl)glycine through the N-acetyl 
group at position 1 of the heterocycle.’7 
X ) FEATURE: 
( A ) NAIVEE/KEY: Modi?ed-site 
( B ) LOCATION: 10 
( D ) OTHER INFORMATION: /label=Modi?ed-site 
/ note= “Cytosine heterocycle is attached to 
N-acetyl(2- aminoethyl)glycine through the N-acetyl 
group at position 1 of the heterocycle.’7 
X ) FEATURE: 
( A ) NAIVEE/KEY: Modi?ed-site 
( B ) LOCATION: 11 
( D ) OTHER INFORMATION: /label=Modi?ed-site 
/ note= “Thymine heterocycle is attached to 
N-acetyl(2- aminoethyl)glycine through the N-acetyl 
5,773,571 
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group at position 1 of the heterocycle.’7 
A i X ) FEATURE: 
( A ) NAIVEE/KEY: Modi?ed-site 
( B ) LOCATION: 12 
( D ) OTHER INFORMATION: /label=Modi?ed-site 
/ note= “Adenine heterocycle is attached to 
N-acetyl(2- aminoethyl)glycine through the N-acetyl 
group at position 9 of the heterocycle.’7 
A i X ) FEATURE: 
( A ) NAIVEE/KEY: Modi?ed-site 
( B ) LOCATION: 13 
( D ) OTHER INFORMATION: /label=Modi?ed-site 
/ note= “Thymine heterocycle is attached to 
N-acetyl(2- aminoethyl)glycine through the N-acetyl 
group at position 1 of the heterocycle.’7 
A i X ) FEATURE: 
( A ) NAIVEE/KEY: Modi?ed-site 
( B ) LOCATION: 14 
( D ) OTHER INFORMATION: /label=Modi?ed-site 
/ note= “Cytosine heterocycle is attached to 
N-acetyl(2- aminoethyl)glycine through the N-acetyl 
group at position 1 of the heterocycle.’7 
A i X ) FEATURE: 
( A ) NAIVEE/KEY: Modi?ed-site 
( B ) LOCATION: 15 
( D ) OTHER INFORMATION: /label=Modi?ed-site 
/ note= “Thymine heterocycle is attached to 
N-acetyl(2- aminoethyl)glycine through the N-acetyl 
group at position 1 of the heterocycle.’7 
A X i ) SEQUENCE DESCRIPTION: SEQ ID NO:8: 
Xaa Xaa Xaa Xaa Xaa 
1 5 
Xaa Xaa Xaa 
( 2 ) INFORMATION FOR SEQ ID NO:9: 
( i )SEQUENCE CHARACTERISTICS: 
( A ) LENGTH: 15 amino acids 
( B )TYPE: amino acid 
( C ) STRANDEDNESS: single 
( D )TOPOLOGY: unknown 
' i ) MOLECULE TYPE: peptide 
( i X )FEATURE: 
( A ) NAIVEE/KEY: Modi?ed-site 
( B ) LOCATION: 1 
( D ) OTHER INFORMATION: /label=Modi?ed-site 
/ note= “Thymine heterocycle is attached to 
N-acetyl(2- aminoethyl)glycine through the N-acetyl 
group at position 1 of the heterocycle.’7 
( i X )FEATURE: 
( A ) NAIVEE/KEY: Modi?ed-site 
( B ) LOCATION: 2 
( D ) OTHER INFORMATION: /label=Modi?ed-site 
/ note= “Guanine heterocycle is attached to 
N-acetyl(2- aminoethyl)glycine through the N-acetyl 
group at position 9 of the heterocycle.’7 
' X ) FEATURE: 
( A ) NAIVEE/KEY: Modi?ed-site 
( B ) LOCATION: 3 
( D ) OTHER INFORMATION: /label=Modi?ed-site 
/ note= “Thymine heterocycle is attached to 
N-acetyl(2- aminoethyl)glycine through the N-acetyl 
group at position 1 of the heterocycle.’7 
' X )FEATURE: 
( A ) NAIVEE/KEY: Modi?ed-site 
( B ) LOCATION: 4 
( D ) OTHER INFORMATION: /label=Modi?ed-site 
/ note= “Adenine heterocycle is attached to 
N-acetyl(2- aminoethyl)glycine through the N-acetyl 
Xaa Xaa 
1O 
Xaa Xaa Xaa Xaa Xaa 
15 































